- Home
- GANX vs CRT Comparison
GANX vs CRT Comparison
Compare GANX & CRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GANX
- CRT
- Stock Information
- Founded
- GANX 2017
- CRT 1991
- Country
- GANX United States
- CRT United States
- Employees
- GANX N/A
- CRT N/A
- Industry
- GANX Biotechnology: Pharmaceutical Preparations
- CRT Oil & Gas Production
- Sector
- GANX Health Care
- CRT Energy
- Exchange
- GANX Nasdaq
- CRT Nasdaq
- Market Cap
- GANX 69.0M
- CRT 65.1M
- IPO Year
- GANX 2021
- CRT 1992
- Fundamental
- Price
- GANX $1.64
- CRT $7.72
- Analyst Decision
- GANX Strong Buy
- CRT
- Analyst Count
- GANX 5
- CRT 0
- Target Price
- GANX $8.20
- CRT N/A
- AVG Volume (30 Days)
- GANX 614.4K
- CRT 23.2K
- Earning Date
- GANX 11-13-2025
- CRT 01-01-0001
- Dividend Yield
- GANX N/A
- CRT 11.47%
- EPS Growth
- GANX N/A
- CRT N/A
- EPS
- GANX N/A
- CRT 0.92
- Revenue
- GANX N/A
- CRT $6,559,820.00
- Revenue This Year
- GANX N/A
- CRT N/A
- Revenue Next Year
- GANX N/A
- CRT N/A
- P/E Ratio
- GANX N/A
- CRT $8.74
- Revenue Growth
- GANX N/A
- CRT N/A
- 52 Week Low
- GANX $1.36
- CRT $7.75
- 52 Week High
- GANX $3.19
- CRT $13.31
- Technical
- Relative Strength Index (RSI)
- GANX 43.33
- CRT 16.28
- Support Level
- GANX $1.55
- CRT $8.46
- Resistance Level
- GANX $1.78
- CRT $8.79
- Average True Range (ATR)
- GANX 0.13
- CRT 0.16
- MACD
- GANX -0.03
- CRT -0.07
- Stochastic Oscillator
- GANX 18.00
- CRT 0.91
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.